Biosimilars Market Size & Share 2026-2035

Biosimilars Market Size

The global biosimilars market was valued at USD 38.7 billion in 2025. The market is estimated to grow from USD 46.4 billion in 2026 to USD 185.2 billion in 2035, growing at a CAGR of 16.6% over the analysis period, according to the latest report published by Global Market Insights Inc.

The market is witnessing substantial expansion, primarily driven by the rising demand for cost-effective biologic therapies and the increasing prevalence of chronic and complex diseases worldwide. The growing burden of diseases such as diabetes, cancer, autoimmune disorders, and inflammatory conditions is significantly increasing the demand for biologic treatments. According to the International Diabetes Federation, the Diabetes Atlas 2025 estimates that nearly 590 million adults globally, representing approximately 11.1% of the adult population, are currently living with diabetes. The continuously expanding diabetic patient population is expected to sustain long-term demand for biologic therapies and related biosimilar products.

The increasing number of patients eligible for biologic therapies is reinforcing the importance of biosimilars in improving treatment accessibility while reducing healthcare expenditure across hospitals, specialty clinics, and outpatient care settings. Growing physician confidence in biosimilar interchangeability, advancements in regulatory frameworks, favorable reimbursement models, and value-based healthcare procurement strategies are further accelerating biosimilar adoption globally without compromising therapeutic efficacy or patient safety.

Biosimilars are highly similar versions of approved biologic medicines that demonstrate comparable safety, efficacy, and quality profiles to reference biologics while offering significantly lower treatment costs. These therapies have emerged as critical alternatives for managing chronic and life-threatening diseases requiring complex biologic interventions, thereby expanding patient access and helping reduce treatment disparities across healthcare systems. Biosimilars undergo extensive analytical, clinical, and regulatory evaluations to establish biosimilarity and therapeutic equivalence with originator biologics.

The market growth was supported by the increasing launch of new biosimilar products, improved reimbursement structures, growing physician and patient awareness, and rising acceptance of biosimilar therapies across multiple therapeutic areas.

Additionally, advancements in bioprocessing technologies, optimization of manufacturing infrastructure, enhanced supply chain capabilities, and increasing investments by pharmaceutical and biotechnology companies in large-scale biosimilar portfolios have further strengthened the market growth trajectory.

Biosimilars Market Trends

• The biosimilars industry is witnessing strong growth as healthcare providers, payers, and governments increasingly prioritize cost-effective alternatives to high-priced biologic therapies. The expiration of patents for several blockbuster biologics, combined with supportive regulatory frameworks across major markets such as the U.S. and Europe, is accelerating biosimilar adoption globally.
• A growing number of biologic therapies have lost patent exclusivity, creating significant opportunities for biosimilar competition and market expansion. By 2025, the U.S. Food and Drug Administration (FDA) had approved 76 biosimilars in the U.S., alongside more than 30,000 generic drugs, reflecting increasing regulatory acceptance and broader treatment availability across multiple therapeutic categories.
• The rising prevalence of chronic diseases including cancer, autoimmune disorders, diabetes, and inflammatory conditions is significantly increasing demand for biologic therapies and related biosimilars. According to GLOBOCAN, nearly 20 million new cancer cases were diagnosed worldwide in 2022, further reinforcing the need for affordable biologic treatment alternatives.
• Increasing physician and patient confidence in biosimilars is contributing to higher adoption rates. Educational initiatives, growing real-world clinical evidence, and expanded post-marketing surveillance programs have strengthened trust regarding the safety, efficacy, and interchangeability of biosimilar products.
• Regulatory advancements are also transforming the biosimilar development landscape. Regulatory authorities such as the European Medicines Agency (EMA) and the FDA are increasingly emphasizing analytical characterization and pharmacokinetic/pharmacodynamic (PK/PD) studies over large comparative clinical trials, helping reduce development costs and shorten commercialization timelines.
• Furthermore, manufacturing expansion initiatives and technological advancements by leading industry participants are improving production scalability and supply chain efficiency. For instance, Sandoz has expanded its biosimilar manufacturing capabilities through investments in Slovenia and strategic acquisitions such as Just-Evotec Biologics, supporting improved production capacity, cost optimization, and global supply reliability.
• Government initiatives focused on reducing drug costs, promoting healthcare competition, and improving patient access to biologic therapies are also supporting market expansion. In the U.S., policy measures under the Inflation Reduction Act, including pricing negotiations and payer incentives, are encouraging healthcare systems to increase biosimilar utilization.

Biosimilars Market Analysis

Based on the product, the biosimilars market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and other products. The recombinant glycosylated proteins segment dominated the market USD 26.2 billion in 2025.     

• The recombinant glycosylated proteins segment holds a significant share of the biosimilars industry due to the increasing demand for complex biologic therapies used in the treatment of chronic and life-threatening diseases. These proteins are produced using recombinant DNA technology in mammalian cell systems, enabling accurate protein folding and essential post-translational modifications such as glycosylation.
• Products within this segment include monoclonal antibodies, erythropoietin, follitropin, and fusion proteins, which are extensively utilized in the management of cancer, autoimmune diseases, diabetes, anemia, and inflammatory disorders.
• The growing prevalence of chronic diseases, combined with patent expirations of several major biologics, continues to stimulate strong demand for recombinant glycosylated biosimilars globally.
• On the other hand, the recombinant non-glycosylated proteins segment, comprising human growth hormone, granulocyte colony-stimulating factor (filgrastim), insulin, and interferons, is projected to grow at a CAGR of 16.8% during the forecast period.
• The segment’s growth is primarily driven by the increasing incidence of diabetes, cancer, and immune-related disorders, alongside rising demand for affordable biologic alternatives across developed and emerging healthcare markets.

Based on application, the biosimilars market is divided into hematology, oncology, autoimmune disease, ophthalmology, growth hormone deficiency, diabetes, and other application. The hematology segment accounted for a significant market share of 29.8% in 2025.   

• The hematology segment dominated the market due to the increasing prevalence of blood disorders and growing demand for cost-effective biologic treatment options. Biosimilars such as erythropoietin are increasingly utilized in the management of anemia, neutropenia, hemophilia, leukemia, and related hematologic conditions.
• Increasing awareness among healthcare professionals and patients regarding the clinical equivalence and safety profile of biosimilars is further supporting market expansion within hematology applications.
• Biosimilars play a critical role in reducing treatment costs while maintaining therapeutic outcomes comparable to reference biologics, thereby improving patient access and supporting sustainable healthcare delivery systems.
• The oncology segment, meanwhile, is expected to witness strong growth at a CAGR of 17.2% over the forecast period, driven by the growing number of biosimilar approvals, increasing cancer prevalence, and rising need for cost-effective oncology biologics.

Based on manufacturing type, the biosimilars market is divided into contract research and manufacturing services, and in-house. The in-house segment dominated the market in 2025 and is expected to reach 134.8 billion by 2035.     

• The in-house manufacturing segment maintains a leading position due to the increasing emphasis on maintaining strict quality control, process optimization, and regulatory compliance during biosimilar production.
• As biosimilar development requires highly precise biologic manufacturing capabilities, companies are increasingly investing in internal manufacturing infrastructure to improve operational efficiency and ensure product consistency.
• In-house manufacturing also enables greater flexibility in responding to evolving regulatory requirements, optimizing production processes, and improving supply chain management.
• These advantages help manufacturers strengthen reliability, reduce long-term production costs, and enhance overall supply chain resilience, reinforcing in-house manufacturing as a preferred strategic model within the biosimilars industry.

Based on technology, the biosimilars market is divided into recombinant DNA technology, mammalian cell culture systems, and other technologies. The recombinant DNA technology segment dominated the market in 2025 with USD 24.4 billion, driven by the growing demand for advanced therapeutics and the rising prevalence of chronic diseases requiring biologic treatments.     

• Recombinant DNA technology serves as the foundational platform for the development of biosimilars, enabling the production of therapeutic proteins, hormones, and biologics that closely resemble originator products in terms of efficacy, safety, and quality.
• The increasing prevalence of chronic diseases requiring biologic therapies, combined with growing demand for advanced therapeutics, continues to drive adoption of recombinant DNA technology across biosimilar manufacturing.
• Technological advancements including gene-editing tools, advanced expression systems, and enhanced protein production efficiency are improving manufacturing scalability while reducing production complexity and costs.
• These innovations are expected to further support biosimilar development across both established and emerging therapeutic applications.
• Meanwhile, the mammalian cell culture systems segment was valued at USD 11 billion in 2025 due to its essential role in producing complex biologics such as monoclonal antibodies and glycoproteins that require advanced post-translational modifications.  

Based on distribution channel, the biosimilars market is divided into hospital pharmacies, specialty pharmacies, and other distribution channels. The hospital pharmacies segment dominated the market in 2025 and is expected to reach 104.8 billion by 2035.       

• Hospital pharmacies play a central role in biosimilar distribution due to their direct involvement in administering biologic therapies for complex and chronic diseases. Hospitals remain primary treatment centers for conditions frequently requiring biologic and biosimilar interventions, making them critical access points for these therapies.
• Hospital pharmacies ensure proper storage, cold-chain management, handling, and administration of biosimilars, which often require specialized clinical oversight and monitoring.
• Additionally, integrated healthcare systems and institutional formularies within hospitals facilitate timely therapeutic switching to biosimilars while supporting reimbursement and procurement efficiency.
• In contrast, specialty pharmacies are gaining importance due to their ability to provide high-touch patient support services, manage complex biologic therapies, improve treatment adherence, and assist patients with reimbursement and formulary navigation, thereby supporting broader biosimilar adoption.

North America Biosimilars Market

North America market held the market share of 29.9% in 2025, and it is anticipated to expand at a 16.5% CAGR over the forecast period.

• North America continues to witness strong biosimilar adoption, driven by rising healthcare expenditures, increasing demand for lower-cost biologic alternatives, and the ongoing expiration of patents for major biologic drugs.
• The region benefits from a highly structured regulatory framework, particularly in the U.S., where streamlined approval pathways and interchangeability guidelines have strengthened physician and patient confidence in biosimilars.
• Increasing payer pressure to reduce treatment costs, alongside formulary optimization and reimbursement incentives, is accelerating the transition toward biosimilar utilization across oncology, autoimmune, and inflammatory disease therapies.
• Further, expanding investments by pharmaceutical companies in biosimilar commercialization, manufacturing capacity, and strategic partnerships continue to reinforce the region’s leadership in the global biosimilars landscape. 

The U.S. biosimilars market size reached USD 10.3 billion in 2025, growing from USD 8.5 billion in 2024.  

• The U.S. biosimilars industry is experiencing rapid expansion as multiple biologic patent expirations create opportunities for increased competition and broader therapeutic access.
• The U.S. FDA continues to support biosimilar approvals through evolving regulatory guidance and streamlined review processes, resulting in a growing number of product launches across key therapeutic areas.
• Increasing provider awareness, expanding real-world evidence supporting biosimilar efficacy and safety, and stronger payer support are contributing to higher prescription volumes and wider market penetration.
• Additionally, hospital systems and integrated healthcare networks are increasingly adopting biosimilars to optimize treatment affordability and reduce long-term biologic spending.

Europe Biosimilars Market

Europe market accounted for USD 15.2 billion in 2025 and is anticipated to show lucrative growth over the forecast period.

• Europe remains one of the most mature markets globally, supported by early regulatory adoption, strong healthcare infrastructure, and favorable reimbursement policies.
• The European Medicines Agency (EMA) has established a robust approval framework that has strengthened clinical confidence and accelerated biosimilar integration across healthcare systems.
• Increasing efforts to control healthcare expenditure, coupled with high acceptance among physicians and pharmacists, continue to stimulate biosimilar utilization in oncology, hematology, diabetes, and autoimmune disorders.
• Furthermore, government-led procurement initiatives, tender systems, and national switching programs are enhancing biosimilar penetration across several European countries.

The Germany biosimilars market is experiencing robust growth in Europe market.  

• Germany continues to be a leading biosimilars industry in Europe, supported by strong healthcare policies focused on reducing biologic treatment costs and improving patient access.
• The country benefits from high physician acceptance, established reimbursement mechanisms, and the presence of leading biosimilar manufacturers and biopharmaceutical companies.
• Increasing adoption of biosimilars across hospitals and outpatient care settings is being reinforced by educational initiatives, formulary inclusion, and favorable procurement strategies.
• Additionally, ongoing investments in manufacturing technologies and collaborations between domestic and international biosimilar developers continue to strengthen Germany’s market position.  

Asia Pacific Biosimilars Market

The Asia Pacific market witnessed substantial growth of 17.4% during the analysis period.

• The regional market is expanding rapidly due to rising healthcare demand, increasing chronic disease prevalence, and growing need for affordable biologic therapies.
• Governments across China, India, South Korea, and Japan are actively supporting biosimilar development through regulatory reforms, accelerated approval pathways, and incentives for local biopharmaceutical manufacturing.
• Increasing investments in biologics research, production infrastructure, and contract manufacturing capabilities are strengthening regional competitiveness in the global biosimilars industry.
• Further, rising awareness among healthcare providers regarding the clinical effectiveness and economic benefits of biosimilars is supporting broader adoption across multiple therapeutic applications.

India biosimilars market is poised to witness high growth over the analysis period.

• India’s market is growing significantly, driven by strong domestic manufacturing capabilities, cost-efficient production, and increasing demand for affordable biologic therapies.
• The country’s large patient population suffering from chronic diseases such as cancer, diabetes, and autoimmune disorders continues to create substantial demand for biosimilars.
• Government support through regulatory streamlining, initiatives promoting biologics manufacturing, and investments in biotechnology infrastructure are accelerating market expansion.
• Additionally, Indian biopharmaceutical companies are strengthening their global presence through partnerships, exports, and development of complex biosimilars including monoclonal antibodies and insulin analogs.

Latin America Biosimilars Market

The Brazil market is experiencing robust growth in Latin America biosimilars industry.

• Brazil’s market is supported by increasing demand for affordable biologic treatments and expanding efforts to improve healthcare accessibility across the country.
• The country’s public healthcare system (SUS) plays a crucial role in promoting cost-effective treatment options and encouraging biosimilar adoption to manage rising healthcare expenditures.
• Regulatory support from ANVISA and increasing participation of multinational and domestic pharmaceutical companies are contributing to a broader biosimilars pipeline and higher product availability.
• Rising prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders is further strengthening demand for biosimilar therapies in Brazil.  

Middle East and Africa Biosimilars Market

The Saudi Arabia market is witnessing substantial growth in Middle East and Africa.

• Saudi Arabia’s biosimilars industry is expanding steadily, driven by healthcare modernization initiatives, increasing chronic disease burden, and growing focus on reducing biologic treatment costs.
• The Saudi Food and Drug Authority (SFDA) has implemented stringent biosimilar approval standards, strengthening confidence in the safety, efficacy, and quality of biosimilar products.
• Government initiatives under Vision 2030 are supporting investments in local biopharmaceutical manufacturing, healthcare infrastructure, and strategic collaborations with global biosimilar developers.
• Increasing adoption of biosimilars across hospitals and specialty care centers is also being supported by efforts to improve healthcare accessibility and optimize pharmaceutical spending across the country.

Biosimilars Market Share

The top 5 companies in the market such as Sandoz, Pfizer, Amgen, Celltrion, and Biocon, accounted for ~55% of the market share in 2025. These companies have maintained their dominance through strong biologics development capabilities, global distribution networks, and continuous portfolio expansion across therapeutic areas such as oncology, immunology, and diabetes.

Companies are also expanding their biosimilar pipelines with a focus on monoclonal antibodies and insulin products, while strengthening their presence in emerging markets. Strategic collaborations, regulatory approvals, and investments in advanced manufacturing technologies are enabling cost efficiencies and faster commercialization. Additionally, improvements in supply chain infrastructure and pricing strategies are enhancing accessibility, driving adoption, and intensifying competition in the market.

Biosimilars Market Companies

Major players operating in the biosimilars industry are:

• Biocon
• Sandoz
• Bio-Thera Solutions
• Pfizer
• Dr. Reddy’s Laboratories
• Amgen
• Teva Pharmaceuticals
• Fresenius Kabi
• Coherus Biosciences
• Apobiologix
• Biocad
• Intas Pharma
• Celltrion
• Zydus Cadila
• Samsung Bioepis

• Sandoz

Sandoz is a global player in biosimilars with a broad, mature portfolio and strong regulatory expertise, enabling rapid market entry and high adoption across multiple therapeutic areas. For example, its biosimilar Hyrimoz (adalimumab) has been widely adopted in Europe and the U.S., offering a cost-effective alternative to Humira while maintaining comparable clinical outcomes.

• Amgen

Amgen leverages deep biologics R&D expertise and large-scale manufacturing capabilities to develop high-quality biosimilars with strong clinical validation. For example, Amjevita (adalimumab biosimilar) was one of the first FDA-approved Humira biosimilars, helping expand patient access to affordable autoimmune therapies.

• Pfizer

Pfizer combines global commercialization strength with advanced biologics development to scale biosimilars rapidly across international markets. For example, Zirabev (bevacizumab biosimilar) has been successfully launched in oncology markets worldwide, providing a lower-cost option for cancer treatment while maintaining efficacy standards.

Biosimilars Industry News

• In December 2025, Fresenius Kabi launched its denosumab biosimilars in Europe, expanding its biosimilars portfolio in bone health and oncology. The launch aims to improve patient access to cost-effective therapies while strengthening the company’s presence in the European biologics market.
• In May 2023, Boehringer Ingelheim received U.S. FDA clearance for the Cyltezo Pen, a new autoinjector option for Cyltezo (adalimumab-adbm), an interchangeable biosimilar to Humira, enhancing patient convenience, supporting self-administration, and improving treatment accessibility for individuals with chronic inflammatory conditions.
• In November 2023, Sandoz launched its adalimumab biosimilar Hyrimoz in additional global markets, expanding access to affordable autoimmune therapies. The launch strengthened Sandoz’s immunology portfolio and supported broader patient adoption through competitive pricing strategies.
• In July 2023, Celltrion launched its biosimilar Yuflyma (adalimumab) in the U.S., offering a high-concentration, citrate-free formulation. The launch supports improved patient convenience and expands competition in the autoimmune therapy segment.
• In June 2022, Biogen Inc. partnered with Samsung Bioepis to launch BYOOVIZ (ranibizumab-nuna), a biosimilar to Lucentis, in the U.S., expanding ophthalmology treatment options, improving patient access to affordable therapies, and strengthening their presence in the competitive market.

The biosimilars market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Recombinant non-glycosylated proteins 
  • Human growth hormone
  • Granulocyte colony-stimulating factor (filgrastim)
  • Insulin
  • Interferon
    • Alfa
    • Beta
• Recombinant glycosylated proteins 
  • Monoclonal antibodies 
    • Infliximab
    • Rituximab
    • Adalimumab
    • Trastuzumab
    • Bevacizumab
  • Erythropoietin
    • Alfa
    • Beta
  • Follitropin
    • Alfa
    • Beta
  • Fusion proteins
• Other products

Market, By Application

• Hematology    
  • Neutropenia  
  • Anemia        
  • Other hematology applications       
• Oncology      
  • Lung cancer  
  • Brain cancer 
  • Breast cancer
  • Cervical cancer       
  • Colorectal cancer     
  • Leukemia      
  • Other Oncology applications
• Autoimmune disease          
  • Arthritis        
    • Rheumatoid arthritis
    • Psoriatic arthritis
    • Juvenile arthritis
    • Ankylosing spondylitis
    • Other arthritis
  • Inflammatory bowel disease (IBD) 
    • Ulcerative colitis
    • Crohn's disease
    • Other IBD
  • Psoriasis       
  • Other autoimmune diseases
• Ophthalmology                 
• Growth hormone deficiency           
• Diabetes                
• Other applications              

Market, By Manufacturing Type

• Contract research and manufacturing services
• In-house

Market, By Technology

• Recombinant DNA technology
• Mammalian cell culture systems
• Other technologies

Market, By Distribution Channel

• Hospital Pharmacies 
• Specialty Pharmacies
• Other distribution channels

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea

• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE